Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Future of myeloma treatment

Ankit Kansagra • 8 Feb 2021
TCT 2021
Multiple Myeloma Antibodies CAR-T

Ankit Kansagra, MD, UT Southwestern Medical Center, Dallas, TX, discusses future directions in the treatment and management of multiple myeloma including novel immunotherapies such as CAR-T and bispecific antibody products in this field, as well as where these therapies fit in the treatment landscape of multiple myeloma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Ankit Kansagra

4:06
An analysis on patients with high-risk multiple myeloma
Ankit Kansagra • 16 Dec 2021
2:56
Autologous stem cell transplant for POEMS Syndrome
Ankit Kansagra • 16 Dec 2021
4:36
Real-world treatment patterns & outcomes of functional high-risk myeloma
Ankit Kansagra • 8 Feb 2021
3:53
KarMMa: characterizing incidence of CRS in R/R myeloma
Ankit Kansagra • 8 Feb 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals